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Abstract
Background: While full disclosure of information on placebo control in participant information leaflets (PILs) in a
clinical trial is ethically required during informed consent, there have been concerning voices such complete disclosures
may increase unnecessary nocebo responses, breach double-blind designs, and/or affect direction of trial outcomes.
Taking an example of acupuncture studies, we aimed to examine what participants are told about placebo controls in
randomized, placebo-controlled trials, and how it may affect blinding and trial outcomes.
Methods: Authors of published randomized, placebo-controlled trials of acupuncture were identified from PubMed
search and invited to provide PILs for their trials. The collected PILs were subjected to content analysis and
categorized based on degree of information disclosure on placebo. Blinding index (BI) as a chance-corrected
measurement of blinding was calculated and its association with different information disclosure was examined. The
impact of different information disclosure from PILs on primary outcomes was estimated using a random effects model.
Results: In 65 collected PILs, approximately 57% of trials fully informed the participants of placebo control, i.e. full
disclosure, while the rest gave deceitful or no information on placebo, i.e. no disclosure. Placebo groups in the studies
with no disclosure tended to make more opposite guesses on the type of received intervention than those with disclosure,
which may reflect wishful thinking (BI −0.21 vs. −0.16; p= 0.38). In outcome analysis, studies with no disclosure significantly
favored acupuncture than those with full disclosure (standardized mean difference− 0.43 vs. −0.12; p= 0.03), probably due
to enhanced expectations.
Conclusions: How participants are told about placebos can be another potential factor that may influence participant
blinding and study outcomes by possibly modulating patient expectation. As we have few empirical findings
on this issue, future studies are needed to determine whether the present findings are relevant to other medical
disciplines and at the same time a routine practice of fully disclosing placebo information in PILs calls for reevaluation.
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Background
Informed consent is a process in clinical research to
ensure participants’ autonomy is respected, and a
document called participant information leaflet (PIL)
is often used to assist the informed decision making
process for the participants by providing adequate
information. Potential trial participants are given thor-
ough information such as study aims, methods, antici-
pated benefits and potential risks of participation
from PILs [1].
Use of a placebo control is often implemented in ran-
domized controlled trials (RCTs) not only to evaluate
the specific effect of a test intervention but also to
effectively blind study participants. Unlike trials of
pharmacological interventions where fabrication of pla-
cebo is relatively easy, however, inventing and/or imple-
menting a placebo control and ensuring masking in
trials assessing non-pharmacological treatments such as
surgery, psychotherapy, or acupuncture, is known to be
more difficult [2]. In non-pharmacological trials, it has
been challenging since detailed information on study hy-
pothesis may compromise the success of blinding while
ensuring participant’s autonomy is an essential ethical
research conduct. Placebo-controlled trials of acupunc-
ture have been in particular criticized for being stingy
with placebo information disclosure to their participants
[3, 4]. Such practice, i.e. partial or no information on
study hypothesis and methods to the study participants,
is line with one of the strategies used in studies assessing
non-pharmacological treatment to achieve successful
blinding [2].
Considering the accumulating evidence supporting
that what information is given to participants before trial
can affect their expectation and behavior both in positive
(i.e. placebo effect) and negative (i.e. nocebo effect) ways
[5–8], and that at the same time, success of blinding en-
sures minimizing risk of bias in a trial, the importance
of information in PILs cannot be disregarded. Moreover,
unlike PILs from conventional drug trials that accurately
disclose the use of placebo [9], PILs of randomized
placebo-controlled trials of acupuncture seem to vary in
the way they describe placebo controls [3]. There
have been few empirical studies examining PILs of
randomized placebo-controlled trials [3], and to our
knowledge, the link between placebo information in
PILs and results of blinding success or study outcomes
has rarely been explored.
In this context, the present study collected PILs of
randomized placebo-controlled trials of acupuncture 1)
to identify what trial participants are told about placebo
controls, and further analyzed 2) whether the informa-
tion on placebo acupuncture procedures from collected
PILs affect the direction/degree of participant blinding
and the trial outcomes.
Methods
This study was approved by the Kyung Hee University
Ethics Committee (KHSIRB-13-052 (EA)).
Study inclusion and PIL collection
PubMed was searched from January 2011 to November
2013 to identify RCTs of manual acupuncture, electroa-
cupuncture, and laser acupuncture where sham or pla-
cebo device or procedure was used for control group.
No language restriction was imposed. For the RCTs pre-
dating 2011, we adopted a list of included studies in
another systematic review of randomized, placebo-
controlled trials of acupuncture with blinding evaluation
data, published in English between 1985 and 2011 [10].
When the list of eligible studies was completed, first
or corresponding authors were invited via e-mail to send
in PILs or informed consent forms used in their trials. If
the authors refused to provide their PILs, or there was
no response after the second reminder, studies were
consequently excluded from our analysis. PILs in lan-
guages other than English were translated into English
by native language speaker.
Content analysis of PILs
Through iterative reading of PILs and following steps of
systematic methods developed for deductive content
analysis [11–13], we reached a consensus of final three
categories by description/explanation of placebo acu-
puncture: “full disclosure of placebo acupuncture (FD)”,
“deceptive disclosure of placebo acupuncture (DD)”, and
“missing information on placebo acupuncture (MI)”.
The PILs had to use specific words such as ‘sham’, ‘pla-
cebo’, or ‘fake’ acupuncture, to be coded in FD category.
PILs that used neutral or deceitful words like ‘group
two’, or simply the ‘control group’ were put into DD cat-
egory even though we trusted that the study authors
never intended to be ‘deceptive’ on purpose in their
PILs. However, if they were followed by additional ex-
planation suggesting that neutrally/deceitfully named
group would involve sham procedures (e.g. to receive
non-acupoint acupuncture), it was considered to be in
the FD category since it was judged that sufficient infor-
mation was given to the study participants to perceive
the existence of placebo acupuncture. For trials with
more than one control groups applying different types of
placebo acupuncture, each placebo group was counted
as a separate unit of data. PILs that missed out on
explaining anything about a placebo control were coded
into MI category.
Information on placebo and blinding
From studies providing results on success of blinding,
Bang’s blinding index (BI) [14] was calculated with 95%
confidence intervals (CI) to further investigate the
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association between information on placebo and effect-
iveness of blinding in trials. Bang’s BI yields a value be-
tween − 1 and 1 for each arm in a study, providing the
proportion of the potentially unblinded beyond chance
[14]. BI of 1 would mean that everyone guessed cor-
rectly, and 0 means guesses were random, whereas − 1
would mean that all guesses were incorrect (e.g. all par-
ticipants in the placebo arm answered that they believe
they received real treatment). The number of partici-
pants in each response of each arm was extracted from
the included studies and more information was sought
from the original authors if necessary. If a study mea-
sured outcome at more than one time point, the data
measured at the end of the last intervention or at the
closest were extracted. Based on BIs, each study was
classified into one out of nine possible blinding scenar-
ios: in brief, random guess, unblinded or opposite guess
is given to each arm in a study, and then, nine blinding
scenarios are possible [10, 14, 15]. The threshold for
blinding classification was random guess for − 0.2 < BI <
0.2; unblinded for BI ≥ 0.2; and opposite guess for BI ≤
− 0.2 [10]. It should be noted that throughout this paper,
the term “unblinded” generally means “more correct
guess,” not broken blinding literally.
Assigned scenarios and calculated BIs were compared
between “disclosure (FD) and no disclosure (DD/MI)”
groups using Mann-Whitney U test or independent
t-test depending on the data distribution by Shapiro-
Wilk test using SPSS (IBM Corp., Version 21.0, Armonk,
NY), and the statistical significance was set at p < 0.05.
Information on placebo and trial outcomes
The aim of this meta-analysis was not to estimate the
effects of acupuncture, but to synthesize the primary
outcomes so that the summarised effects of studies from
disclosure and no disclosure groups can be compared.
For this analysis, following strategies were used to
choose the outcome: (1) whether it is continuous out-
come or dichotomous outcome, it should have data that
are needed to calculate standardized mean difference
(SMD) and standard deviation (SD); (2) the timing
should be either indicated primary end-point or as close
as possible to the last treatment session; (3) in the ab-
sence of predefined single main outcome measure, com-
monly used outcome in similar studies (e.g. visual
analogue scale (VAS) for pain studies) was chosen or; (4)
an outcome that reports clear data (e.g. if one outcome
is reported in a table with specific values whereas an-
other outcome is reported in a figure without any accur-
ate values, the former) was chosen; (5) if a trial had
more than one placebo group, the data were pooled sep-
arately as they were in content analysis, and number of
participants in the shared intervention group was di-
vided evenly [16]. For calculating SMD and SD from
dichotomous outcomes, we used a formula, SMD ¼
ffiffi
3
p
π
lnOR (OR, odds ratio) [17]. A random-effects model
with the generic inverse variance method was adopted
to estimate SMD and 95% CI using Review Manager
(The Nordic Cochrane Centre, Version 5.3.4, Copenhagen,
Denmark). The I2 test was used to examine heterogeneity
across the studies, and different PIL categories were sub-
ject to the subgroup analysis to investigate whether the es-
timates in the primary outcome varied between subgroups
(FD or DD). In this meta-analysis using a Review Manager
software, this test was undertaken using Cochran’s Q test
and Higgins’ I2 by comparing the subtotal estimates
between the subgroups. In addition, a post hoc ana-
lysis grouped studies by its originating region (Asia
and Non-Asia) in each PIL category and tested in the
same manner above whether the estimates in the outcome
of interest varied in different regions.
Results
Included PILs
The initial PubMed search yielded 216 records. Among
them, 107 articles were excluded for not meeting our in-
clusion criteria: studies with no acupuncture group per
inclusion criteria (n = 39), non-RCTs (n = 26), protocols
only (n = 20), studies with no placebo acupuncture con-
trol group (n = 19), animal studies (n = 2), and a dupli-
cate (n = 1) [18, 19]. Additional 53 studies included in a
previous systematic review [10] of placebo-controlled
trials of acupuncture were then added to the remaining
109 studies. One study [20] from the adopted list was re-
placed by its original trial as it was identified as an add-
itional report [21]. Two studies overlapping with our
own search result were excluded, leaving a total of final
160 studies subject to invitation to share PILs.
The invitation e-mail was sent to the trialists in 24
countries in total, with China and USA on the top with
29 trials followed by Germany, Korea, and UK. Among
100 studies that replied to our invitation letter (62.5% of
response rate), 63 studies provided PILs. In addition,
one author generously provided two extra PILs on top of
the requested documents and final 65 PILs from 15
different countries were collected for analysis (Fig. 1;
Additional file 1: Appendix 1).
Placebo control groups and information disclosure in PILs
Types of placebo acupuncture implemented in the in-
cluded studies were diverse and could be simply
divided into three groups; non-penetrating placebo
acupuncture, penetrating placebo acupuncture, and
others (Additional file 1: Appendices 2 and 3).
Through the content analysis of information on pla-
cebo given to study participants, extracted data of 70
placebo control groups from 65 PILs were categorized
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into three groups. More than half of the PILs (57.1%)
were straightforward to the participants when they were
introducing placebo acupuncture control, and these
were classified as FD group. In the 2nd group named as
DD group, no words or phrases that clearly indicated
placebo acupuncture would be used (35.7%), i.e., rather
deceptive words such as ‘different (7),’ ‘control (5),’ ‘group
1 or group 2 (2),’ ‘non-traditional (2),’ ‘not typical (2),’
and ‘test (2),’ were given. Remaining five PILs (7.1%) fell
into MI group and they missed out on explaining any-
thing about a placebo control group. Detailed results of
the content analysis are provided in Additional file 1:
Appendix 4.
Our analysis of PILs by country of its origin revealed
that PILs from non-Asian countries were more likely to
fully inform the study participants of placebo acupunc-
ture compared with those from Asian countries (χ2 (1,
n = 70) = 7.099, p = 0.008; Additional file 1: Appendix 5).
Information on placebo and blinding
Data for BI calculation were available in 26 studies (Fig. 1).
With one study providing three independent data sets [22],
28 sets of BI were calculated in total. Among the nine
possible scenarios of blinding (Table 1), 50% of the studies
(n = 14) were counted into blinding scenarios 1 (random
guess for both acupuncture and control groups) and 5 (un-
blinded for acupuncture group and opposite guess for con-
trol group), which are assumed to be the ideal blinding
situation. In the scenarios considered possibly problematic,
which are blinding scenarios 4 (unblinded for both acu-
puncture and control groups) and 6 (unblinded for acu-
puncture group and random guess for control group),
35.7% of the studies (n = 10) were included. When the
number of studies that belonged to ideal or possibly prob-
lematic blinding scenarios was compared within each cat-
egory, DD/MI category had a higher rate of studies with
ideal blinding than FD category (Table 1). The number of
Fig. 1 Flow diagram for selection of studies. aAmong included studies, only those providing extractable data for calculating blinding index were included
here. bStudies that clearly indicated and reported specific data of primary outcome were eligible for meta-analysis. RCT, randomized controlled trial
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studies in S1 and S5, the ideal scenarios, was more than
double the number of studies in S4 and S6 in DD/MI cat-
egory (7 studies vs. 3 studies), whereas the numbers were
the same in FD category (5 studies vs. 5 studies).
BI values for each study were calculated with their
95% CI (Fig. 2). Average BI values for real acupuncture
groups in FD and DD/MI categories were 0.42 and 0.41,
respectively. In other words, 42% (95% CI 0.23 to 0.62)
of participants in the real acupuncture groups who were
given full disclosure of placebo information and 41%
(95% CI 0.21 to 0.61) in the real acupuncture groups
from the studies with no disclosure (DD/MI category)
correctly guessed that the given treatment was real acu-
puncture beyond chance (Fig. 2a and b). On the other
Table 1 Frequencies of nine different blinding scenarios by PIL categories
Scenario Experimental Group Control Group Possible Interpretation [10] FD % (n) DD/MI % (n)
S1 Random guess Random guess Possibly most ideal from the scientific or statistical perspective 11.8 (2) 18.2 (2)
S2 Random guess Opposite guess Rare 5.9 (1) 9.1 (1)
S3 Random guess Unblinded Possibly little treatment effect and no effect in control group 5.9 (1) 0 (0)
S4 Unblinded Unblinded Possibly problematic 11.8 (2) 9.1 (1)a
S5 Unblinded Opposite guess Ideal – patients tend to have wishful thinking, strong placebo
effect, and any treatment administered is perceived as real
treatment
29.4 (5) 45.5 (5)
S6 Unblinded Random guess Possibly problematic – patients in control group do not know
what to expect in the absence of treatment
29.4 (5) 18.2 (2)
S7 Opposite guess Opposite guess Rare 0 (0) 0 (0)
S8 Opposite guess Random guess Rare 5.9 (1) 0 (0)
S9 Opposite guess Unblinded No treatment effect at all or patients may have low expectations 0 (0) 0 (0)
There were 17 and 11 studies in FD, and DD/MI category, respectively. aAmong the 11 studies in DD/MI category, only one article belonged to MI category
Here, the term “Unblinded” generally means “More correct guess,” not broken blinding literally
Random guess: −0.2 < BI < 0.2; unblinded: BI ≥ 0.2; opposite guess: BI ≤ −0.2 [10]
BI Blinding index, DD Deceptive disclosure of placebo acupuncture, FD Full disclosure of placebo acupuncture, MI Missing information on placebo acupuncture,
PIL participant information leaflet
A B
C D
Fig. 2 BI values by PIL categories. a BI values of real acupuncture group from FD category; b BI values of real acupuncture group from DD/MI
category; c BI values of placebo acupuncture group from FD category; d BI values of placebo acupuncture group from DD/MI category. Negative
values indicate opposite guessing of allocated arm, 0 refers to random guessing, and positive values indicate correct guessing of allocated arm (e.g.
guessed real acupuncture when assigned to real acupuncture). This study defined BI value between − 0.2 and 0.2, presented in the shaded area in
each graph, as random guess [10]. BI, blinding index; DD, deceptive disclosure of placebo acupuncture; FD, full disclosure of placebo acupuncture; MI,
missing information on placebo acupuncture; PIL, participant information leaflet
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hand, 16% of the participants in the placebo group in
the studies with full information disclosure believed that
they received real acupuncture beyond chance (− 0.16,
95% CI −0.39 to 0.06, Fig. 2c). In the groups without ad-
equate information on placebo acupuncture, 21% of the
participants in the placebo group guessed they were
given real acupuncture (− 0.21, 95% CI −0.47 to 0.05,
Fig. 2d). There was no significant difference in BI values
of both real and placebo acupuncture groups between the
two categories, i.e. disclosure vs. no disclosure (real acu-
puncture, p = 0.92, independent t-test; placebo acupunc-
ture, p = 0.38, Mann-Whitney U test).
Information on placebo and trial outcomes
Among 22 studies of which SMD and SD were available,
two studies had two placebo control groups, leaving
24 units of data for a meta-analysis. No study from MI
category provided adequate data for pooling. The meta-
analysis of studies in DD category showed acupuncture
produced better clinical outcomes compared to placebo
acupuncture (SMD −0.43, 95% CI −0.68 to − 0.18, p =
0.0006; Fig. 3), whereas the studies of FD category found
no significant difference between real and placebo groups
(SMD −0.12, 95% CI −0.26 to 0.01, p = 0.08; Fig. 3). When
two categories were assigned as subgroups, a test for sub-
group differences also showed that pooled effect for real
acupuncture from DD category is greater than that of FD
category (χ2 = 4.54, p = 0.03, I2 = 78.0%; Fig. 3).
A post hoc subgroup analysis was performed within
each category to see if there is any regional difference in
trial results, but this analysis could not confirm the re-
sults of Vickers et al. [23] which found Asian countries
were more likely to produce positive findings in acu-
puncture studies. In both categories, there was no differ-
ence between studies from Asian and non-Asian
countries (test for subgroup differences; FD, p = 0.88;
DD, p = 0.23; Additional file 1: Appendix 6).
Discussion
Principal findings of the study
We analyzed PILs of placebo-controlled acupuncture tri-
als to see how placebo acupuncture was described to the
study participants. Approximately 57% of the studies
fully informed the participants of placebo acupuncture
while the rest of the studies either gave deceitful or no
information on placebo. A half of the studies were
A
B
Fig. 3 Clinical outcomes by PIL categories. Anonymized studies are from (a) FD category, and (b) DD category, respectively. A test for subgroup
differences indicates that studies from DD category report greater effects of real acupuncture compared to those from FD category. CI, confidence
intervals; DD, deceptive disclosure of placebo acupuncture; FD, full disclosure of placebo acupuncture; PIL, participant information leaflet; SE, standard
error; Std., standardized
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evaluated as ideally blinded. When BI values of the in-
cluded studies were compared between FD and no dis-
closure (DD/MI) categories, placebo groups in the latter
were more likely than those in FD category to make op-
posite guesses on the intervention, i.e., guessed that they
have received real acupuncture. Although this difference
did not reach statistical significance, it may reflect more
wishful thinking of placebo groups in no disclosure cat-
egory than those in FD category. Studies with no disclosure
reported greater treatment effects for real acupuncture than
those with FD, possibly due to enhanced expectations.
Possible explanations and implications of the study for
clinicians and researchers
In medicine, whether in clinical or research settings,
there are high levels of ethical requirements that are ex-
pected to be met. Respecting trial participants’ autonomy
by providing them adequate amount of information is
one of those requisites for ethical practice in medical re-
search, and often, the PIL is presented to the partici-
pants as a tool to meet the requirements. The main
purpose of the PIL, in this sense, would be to help par-
ticipants voluntarily make a well-informed decision on
the introduced matter. When the control intervention of
the trial involves a placebo, there has to be even more
cautious approach and full disclosure of such informa-
tion [1, 24, 25]. On the other hand, there are concerns
on too much information may disadvantage the partici-
pants, as in increasing a nocebo effect [26, 27], or result-
ing in a lengthy document that rather compromises
participants’ understanding [28]. Some argue that PILs
are not in a reader friendly language [29], nor come with
decision making aids [30]. Therefore, for a PIL to fully
serve its purpose, it seems necessary to inform the par-
ticipants in a way that is not only being clear about what
is going to happen, but also being considerate of how it
actually helps them to make an informed decision.
There has been a concerning voice that placebo-
controlled trials of acupuncture are reluctant to fully
disclose the existence of placebo acupuncture control
[3, 4]. However, findings of the current study show
change of practice ever since, showing number of
studies that accurately inform the use of placebo con-
trol, being more than a half: out of 70 placebo groups
from 65 PILs, 40 were classified into FD category,
and 12 of those 40 were from the older studies that
were included in the previous review. These findings
confirm that acupuncture trials are also trying to con-
form to the ethical requirements [31, 32]. However, at
the same time, given that there is still a room for im-
provement in providing complete and accurate infor-
mation about placebos even in trials assessing
conventional medicine [9], and device-based interven-
tions are facing challenges in maintaining blinding
with a full disclosure of placebos [33], information
disclosure in PIL may be taken as an issue in clinical
research across the board.
In East Asian countries, even after western medicine’s
addition to the system, traditional medicine is still rou-
tinely used [34, 35]. As a result, acupuncture is easily
accessible and embedded in cultural background. There-
fore, participants as well as the researchers of acupunc-
ture trials are assumed to be more familiar with
acupuncture compared to those in non-Asia region [36].
This brings concern to Asian researchers that the study
participants will easily distinguish real from placebo acu-
puncture. The rationale behind such fear is not simple,
as studies examining the influence of the participant’s
previous experience on detecting placebo acupuncture
presented conflicting results [37, 38]. The notion that
blinding may be hampered if trial participants are fully
informed on details of placebo acupuncture, is partly ex-
plained in our BI analysis. While 21% of the participants
in the placebo acupuncture group from DD/MI category
made incorrect guesses beyond chance, i.e. they believed
they received real acupuncture, 16% of those in the pla-
cebo acupuncture group from FD category made such
guesses. It could be interpreted that though not statisti-
cally significant, the participants on the placebo acu-
puncture arm who were not very well informed about
placebo acupuncture tended to guess that they received
real acupuncture more than participants in FD category
did. It reflects participants’ wishful thinking, which may
lead to an augmented placebo effect [10]. This finding is
in line with the result from the Cochrane review of all
placebo interventions where a higher placebo effect was
reported in trials without correct information of placebo
than those with correct information [39]. An altered pla-
cebo labeling study also has shown that placebo effect
goes higher as the label on placebo changes from pla-
cebo, uncertain to valid medicine [40]. Given our BI ana-
lysis and the results from other relevant studies, the
hypothesis can be generated that full disclosure of pla-
cebo in PILs may undermine successful blinding of par-
ticipants and this should be systematically evaluated in
the future studies.
A meta-epidemiological study has reported that well
maintained blinding resulted in a smaller effect of
intervention compared to non-blinded trials [41]. In the
present study, however, pooled effect size of trials in DD
category, which showed better blinding results than FD
category, was greater than that of FD category. There
could be two possible explanations. First, we may sus-
pect that informing the presence of placebo acupuncture
in detail lowered the participants’ expectation and as a
result, possibly undermined the effect of real acupunc-
ture in studies in FD category, whereas the participants’
expectation was maintained or enhanced in DD category
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and the trials favored acupuncture to a larger extent.
This is supported by a pooled analysis from four, large
population based German RCTs which demonstrated
higher expectation was associated with a better outcome
regardless of given treatment [42]. Considering that our
study was not designed to directly measure participants’
expectation of treatment, however, we cannot estimate
to what extent expectation contributed to greater effect
size from the studies in DD category than those in FD
category. Another explanation is that the treatment ef-
fect in DD category is rather overestimated due to inves-
tigator’s bias. Not only the patients but also trialists have
expectations, wittingly or unwittingly [43]. Considering
the fact that more studies in DD/MI category originated
from Asia, which is an acupuncture friendly region
where researchers are eager to prove its efficacy, than
FD category, it may be trialists’ expectation on top of
the participants’ expectation that resulted in such higher
estimation. Besides, when we evaluated whether out-
come assessor was blinded to the intervention in the
included studies, the proportion of studies with appro-
priate blinding for outcome assessor was slightly lower
in DD category (20 out of 25, 80%) compared to FD cat-
egory (33 out of 40, 82.5%). This too supports investiga-
tor bias may have possibly played a part in
overestimation of treatment effect in the studies of DD
category. Nonetheless, the fact that only small number
of studies were included here and that this is merely ob-
servational in nature allows for an interpretation in a
narrow context. To elucidate complicated relationships
between PILs, blinding, and outcomes of a trial, further
studies designed to compare the links between those are
warranted for more discussion.
Strengths and weaknesses of the study
One of the strengths of this study is that we are address-
ing a fundamental question over so-called routine clin-
ical research procedures. We tried to provide a more
comprehensive understanding of any association of
placebo disclosure in PILs with methodological issues in
clinical research, i.e. blinding, and the effect size. Previ-
ous studies have usually focused on ethics [44], readabil-
ity [45], or comprehensiveness [46], but few studies
explored association of pre-trial information on placebo
with blinding and trial outcomes, which definitely
requires further investigations from a different point of
view. Another strength would be that it encompasses
qualitative and quantitative research designs. Collected
PILs were subject to systematic qualitative content ana-
lysis method [12]. Then, numerical analyses such as calcu-
lating BI and effect size were conducted in conjunction
with the results from content analysis. Such integrated
method can help science achieve better understanding of
its discoveries [47].
Some limitations also should be noted. Firstly, not all
included documents were written in English and simple
analysis such as word count, page count, or readability
calculation was not feasible. Although, all documents
were carefully translated into proper English by experts
then analyzed in the main analysis in a standardized
way, we cannot rule out the possibility that some subtle
nuance of original language was not delivered in transla-
tion. Secondly, the number of studies included in blind-
ing and outcome analysis was too small compared to
that of all included studies for content analysis, which
might have made it difficult to detect statistically signifi-
cant differences, if any, thus to draw any firm conclu-
sion. Even so, the number of studies included in the
main content analysis was larger than 16 of a previous
study [3] and was similar to the suggested ‘medium’
sample size for integrated qualitative-quantitative re-
search [47]. More importantly, this study accomplished
to collect the documents from many different countries
of different environment and culture while the previous
study had documents mostly from only few countries
such as Germany, UK and USA. This diversity of docu-
ments in the present study made it possible to explore
rich source of data. Last but not the least, the actual per-
ception of the information on PIL by study participants
may differ from degree of information disclosure judged
in our study. Participants’ understanding and memory of
the contents of PILs vary [33] and their behavior may be
influenced by other multiple factors such as prior know-
ledge, health literacy, preference and expectation.
Unanswered questions and future research
Our findings raise questions on routinely accepted in-
formed consent procedures: ethical standard requires
every detailed information including placebo should be
given to study participants. Placebo information in other
than acupuncture trials, however, has been reported far
from fully informing [9] and what information is pro-
vided to the patient about side effects is known to
modulate treatment responses often to enhance nocebo
effect [8, 48]. Moreover, as we have few empirical find-
ings on how patients are told about placebo may affect
blinding and study outcomes, future studies are needed
to examine this unanswered question.
Other than methodological qualities such as allocation
concealment or blinding that are known to affect the dir-
ection or magnitude of treatment effect [41, 49], we found
information on placebo in PIL may be another potential
factor for influencing the study outcome by possibly
modulating patient expectation in the informed consent
process. Therefore, further in-depth studies utilizing both
qualitative and quantitative methods are warranted to bet-
ter understand complicatedly intertwined factors in PILs,
blinding, and outcomes of placebo-controlled trials.
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Conclusions
How participants are told about placebos may be an-
other potential factor that may influence participant
blinding and the study outcome. As we have few empir-
ical findings on this issue, future studies are needed to
determine whether the present findings are relevant to
other medical disciplines and at the same time a routine
practice of fully disclosing placebo information in PILs
calls for reevaluation.
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